| pubmed-article:1719321 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1719321 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:1719321 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:1719321 | lifeskim:mentions | umls-concept:C0072980 | lld:lifeskim |
| pubmed-article:1719321 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1719321 | lifeskim:mentions | umls-concept:C0729218 | lld:lifeskim |
| pubmed-article:1719321 | pubmed:issue | 8778 | lld:pubmed |
| pubmed-article:1719321 | pubmed:dateCreated | 1991-12-19 | lld:pubmed |
| pubmed-article:1719321 | pubmed:abstractText | Graft-vessel disease (GVD) limits the long-term survival of heart-transplant patients, and this effect has not been altered by use of cyclosporin for immunosuppression. We compared the effects of the immunosuppressants cyclosporin, FK506, and rapamycin on GVD in a rat-heart transplantation model. Allografted hearts from rats treated with 1 mg/kg FK506 for 50 days showed the same degree of myocardial rejection but a significantly worse (p less than 0.05) grade of GVD compared with grafted hearts from rats treated with 1.5 mg/kg cyclosporin for the same time. 2 mg/kg FK506 for 50 days prevented cellular rejection but GVD was as severe as that found with 1 mg/kg FK506. Moderate GVD was present in two of five allografted hearts after treatment with 4 mg/kg FK506. 1.5 mg/kg rapamycin for 50 days was an effective inhibitor of rejection and GVD. Based on our results in rats, the possibility that GVD may occur in human heart-transplant recipients treated with FK506 cannot be excluded. | lld:pubmed |
| pubmed-article:1719321 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1719321 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1719321 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1719321 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1719321 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1719321 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1719321 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1719321 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1719321 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1719321 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1719321 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:1719321 | pubmed:issn | 0140-6736 | lld:pubmed |
| pubmed-article:1719321 | pubmed:author | pubmed-author:BillinghamM... | lld:pubmed |
| pubmed-article:1719321 | pubmed:author | pubmed-author:MorrisR ERE | lld:pubmed |
| pubmed-article:1719321 | pubmed:author | pubmed-author:MeiserB MBM | lld:pubmed |
| pubmed-article:1719321 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1719321 | pubmed:day | 23 | lld:pubmed |
| pubmed-article:1719321 | pubmed:volume | 338 | lld:pubmed |
| pubmed-article:1719321 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1719321 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1719321 | pubmed:pagination | 1297-8 | lld:pubmed |
| pubmed-article:1719321 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:meshHeading | pubmed-meshheading:1719321-... | lld:pubmed |
| pubmed-article:1719321 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1719321 | pubmed:articleTitle | Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. | lld:pubmed |
| pubmed-article:1719321 | pubmed:affiliation | Department of Cardiothoracic Surgery, Stanford University School of Medicine, California. | lld:pubmed |
| pubmed-article:1719321 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1719321 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1719321 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1719321 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1719321 | lld:pubmed |
